Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
Abstract
Developing a cross-clade, globally effective HIV vaccine remains crucial for eliminating HIV.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 09, 2022
- Source ID
- 10.1093/infdis/jiac445
Entities
People
- Christy Comeaux
- Colleen F Kelley
- Dan H. Barouch
- Daniel J. Stieh
- David C. Montefiori
- Dimitri Goedhart
- Etienne Karita
- Frank Tomaka
- Galit Alter
- Georgia D. Tomaras
- Guido Ferrari
- Hanneke Schuitemaker
- Hong Van Tieu
- Ian Frank
- Jack Heptinstall
- James G. Kublin
- Jennifer A Johnson
- Joseph Nkolola
- Julie A. Ake
- Julie McElrath
- Kathryn E. Stephenson
- Katleen Callewaert
- Kenneth Mayer
- Kristen W Cohen
- Lauren Peter
- Lawrence Corey
- Lindsey R. Baden
- Lorenz Scheppler
- Magda Sobieszczyk
- Maria G Pau
- Matthew H Collins
- Merlin L Robb
- Michael Keefer
- Michael S Seaman
- Michal Sarnecki
- Nadine Rouphael
- Paul A Goepfert
- Philipp Mann
- Sheetal Sawant
- Srilatha Edupuganti
- Stephen C. De Rosa
- Stephen R Walsh
- Steven Nijs
- Susan Buchbinder
- The Ascent/hvtn118/hpx2003 Study Team
- Trevor A Crowell
- Varun K Phadke
- Zelda Euler
Organizations
- Beth Israel Deaconess Medical Center
- Duke University
- Emory University
- Fred Hutchinson Cancer Center
- Gates Foundation
- Harvard Medical School
- Harvard University
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Janssen Pharmaceutica
- Janssen Vaccines
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- United States Department of Defense
- University of Alabama at Birmingham